Education
About Us
Working with TipRanks
Follow Us
Bajaj Healthcare Ltd (IN:BAJAJHCARE)
:BAJAJHCARE
BAJAJHCARE Stock Chart & Stats
₹418.50
-₹31.80(-5.51%)
At close: 4:00 PM EST
₹418.50
-₹31.80(-5.51%)
Day’s Range― - ―
52-Week Range₹312.05 - ₹744.90
Previous CloseN/A
Volume215.90K
Average Volume (3M)4.99K
Market Cap
₹10.14B
Enterprise Value₹12.39B
Total Cash (Recent Filing)₹44.51M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)20.9
Beta1.02
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)4.96
Shares Outstanding31,583,252
10 Day Avg. Volume2,706
30 Day Avg. Volume4,987
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)4.64
Price to Sales (P/S)3.98
P/FCF Ratio-124.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA reported ~17.3% revenue growth rate signals durable demand expansion across the company’s product lines. Over a 2-6 month horizon this underpins scale benefits, supports margin recovery potential if costs are managed, and provides a foundation to deleverage if cash conversion improves.
Diversified Product & Market MixOperating both API/intermediate manufacturing and finished formulations for domestic and export markets creates multiple revenue channels. This B2B plus contract manufacturing mix reduces single-market concentration risk and smooths demand cycles, giving longer-term resilience.
Improving Equity RatioAn improving equity ratio strengthens solvency over time and provides a larger buffer against shocks, improving access to financing and capacity to fund compliance or capex. This structural improvement supports durability even while leverage needs further reduction.
Bears Say
High LeverageMaterial leverage raises financing and refinancing risk and increases interest expense exposure. Over months this constrains strategic flexibility, limits ability to invest in capacity or quality upgrades, and amplifies downside if revenue or input-cost pressures persist.
Weak Cash ConversionInconsistent operating cash flow and negative free cash flow indicate profits are not reliably translating to liquidity. Reliance on external financing to bridge gaps elevates liquidity risk and hampers the company's ability to organically reduce debt or fund working capital over the medium term.
Margin PressureSustained declines in gross and EBIT margins point to cost or mix pressures that erode core profitability before one-offs. If persistent, margin erosion weakens cash generation, reduces competitiveness, and limits capacity to absorb raw material inflation or invest in R&D and quality systems.
Bajaj Healthcare Ltd News
BAJAJHCARE FAQ
What was Bajaj Healthcare Ltd’s price range in the past 12 months?
Bajaj Healthcare Ltd lowest stock price was ₹312.05 and its highest was ₹744.90 in the past 12 months.
What is Bajaj Healthcare Ltd’s market cap?
Bajaj Healthcare Ltd’s market cap is ₹10.14B.
When is Bajaj Healthcare Ltd’s upcoming earnings report date?
Bajaj Healthcare Ltd’s upcoming earnings report date is Jun 02, 2026 which is in 88 days.
How were Bajaj Healthcare Ltd’s earnings last quarter?
Bajaj Healthcare Ltd released its earnings results on Jan 16, 2026. The company reported ₹4.963 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.963.
Is Bajaj Healthcare Ltd overvalued?
According to Wall Street analysts Bajaj Healthcare Ltd’s price is currently Overvalued.
Does Bajaj Healthcare Ltd pay dividends?
Bajaj Healthcare Ltd pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.24%. See more information on Bajaj Healthcare Ltd dividends here
What is Bajaj Healthcare Ltd’s EPS estimate?
Bajaj Healthcare Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bajaj Healthcare Ltd have?
Bajaj Healthcare Ltd has 31,583,252 shares outstanding.
What happened to Bajaj Healthcare Ltd’s price movement after its last earnings report?
Bajaj Healthcare Ltd reported an EPS of ₹4.963 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.8%.
Which hedge fund is a major shareholder of Bajaj Healthcare Ltd?
Currently, no hedge funds are holding shares in IN:BAJAJHCARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bajaj Healthcare Ltd
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, and supplies amino acids, nutritional supplements, and active pharmaceutical ingredients (APIs) for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company's product portfolio consists of various APIs in the therapeutic categories of anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, antihelmintic, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, venous disease, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, anticonvulsant, lipotropic agents, nootropic, vasoprotective/ antihemorrhagic, cardiovascular agent, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It also provides formulations in the form of tablets, capsules, and powder, as well as impurities. In addition, the company exports its products. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India.
Technical Analysis
Bliss Gvs Pharma Limited
―
Hester Biosciences Limited
―
Jagsonpal Pharmaceuticals Ltd.
―
Syncom Formulation (India) Ltd.
―
Themis Medicare Limited
―